Related Experiment Video
Updated: Aug 6, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Navigating NTRK in Non-small Cell Lung Cancer (NSCLC): A Patient Perspective
Justin Gainor1, Leah Bundy2, Stevan Bradford3
1Center for Thoracic Cancers, Massachusetts General Hospital, Boston, USA.
Cureus
|July 24, 2026
Summary
NTRK fusion-positive non-small cell lung cancer (NSCLC) requires clear communication. Understanding patient experiences with diagnosis, targeted therapy, and rare genomic alterations improves personalized cancer care.
Area of Science:
- Oncology
- Genomics
- Patient Advocacy
Background:
- NTRK fusion-positive non-small cell lung cancer (NSCLC) is a rare subtype.
- Effective communication and understanding patient experiences are crucial for personalized care.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...